Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative

R. Aggarwal, LG. Rider, N. Ruperto, N. Bayat, B. Erman, BM. Feldman, CV. Oddis, AA. Amato, H. Chinoy, RG. Cooper, M. Dastmalchi, D. Fiorentino, D. Isenberg, JD. Katz, A. Mammen, M. de Visser, SR. Ytterberg, IE. Lundberg, L. Chung, K. Danko, I....

. 2017 ; 76 (5) : 792-801.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu konsensus - konference, časopisecké články, směrnice pro lékařskou praxi, validační studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023151

To develop response criteria for adult dermatomyositis (DM) and polymyositis (PM). Expert surveys, logistic regression, and conjoint analysis were used to develop 287 definitions using core set measures. Myositis experts rated greater improvement among multiple pairwise scenarios in conjoint analysis surveys, where different levels of improvement in 2 core set measures were presented. The PAPRIKA (Potentially All Pairwise Rankings of All Possible Alternatives) method determined the relative weights of core set measures and conjoint analysis definitions. The performance characteristics of the definitions were evaluated on patient profiles using expert consensus (gold standard) and were validated using data from a clinical trial. The nominal group technique was used to reach consensus. Consensus was reached for a conjoint analysis-based continuous model using absolute per cent change in core set measures (physician, patient, and extramuscular global activity, muscle strength, Health Assessment Questionnaire, and muscle enzyme levels). A total improvement score (range 0-100), determined by summing scores for each core set measure, was based on improvement in and relative weight of each core set measure. Thresholds for minimal, moderate, and major improvement were ≥20, ≥40, and ≥60 points in the total improvement score. The same criteria were chosen for juvenile DM, with different improvement thresholds. Sensitivity and specificity in DM/PM patient cohorts were 85% and 92%, 90% and 96%, and 92% and 98% for minimal, moderate, and major improvement, respectively. Definitions were validated in the clinical trial analysis for differentiating the physician rating of improvement (p<0.001). The response criteria for adult DM/PM consisted of the conjoint analysis model based on absolute per cent change in 6 core set measures, with thresholds for minimal, moderate, and major improvement.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023151
003      
CZ-PrNML
005      
20190124083505.0
007      
ta
008      
170720s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/annrheumdis-2017-211400 $2 doi
035    __
$a (PubMed)28385805
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Aggarwal, Rohit $u University of Pittsburgh, Pittsburgh, Pennsylvania, USA. $7 gn_A_00002139
245    10
$a 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative / $c R. Aggarwal, LG. Rider, N. Ruperto, N. Bayat, B. Erman, BM. Feldman, CV. Oddis, AA. Amato, H. Chinoy, RG. Cooper, M. Dastmalchi, D. Fiorentino, D. Isenberg, JD. Katz, A. Mammen, M. de Visser, SR. Ytterberg, IE. Lundberg, L. Chung, K. Danko, I. García-De la Torre, YW. Song, L. Villa, M. Rinaldi, H. Rockette, PA. Lachenbruch, FW. Miller, J. Vencovsky, . ,
520    9_
$a To develop response criteria for adult dermatomyositis (DM) and polymyositis (PM). Expert surveys, logistic regression, and conjoint analysis were used to develop 287 definitions using core set measures. Myositis experts rated greater improvement among multiple pairwise scenarios in conjoint analysis surveys, where different levels of improvement in 2 core set measures were presented. The PAPRIKA (Potentially All Pairwise Rankings of All Possible Alternatives) method determined the relative weights of core set measures and conjoint analysis definitions. The performance characteristics of the definitions were evaluated on patient profiles using expert consensus (gold standard) and were validated using data from a clinical trial. The nominal group technique was used to reach consensus. Consensus was reached for a conjoint analysis-based continuous model using absolute per cent change in core set measures (physician, patient, and extramuscular global activity, muscle strength, Health Assessment Questionnaire, and muscle enzyme levels). A total improvement score (range 0-100), determined by summing scores for each core set measure, was based on improvement in and relative weight of each core set measure. Thresholds for minimal, moderate, and major improvement were ≥20, ≥40, and ≥60 points in the total improvement score. The same criteria were chosen for juvenile DM, with different improvement thresholds. Sensitivity and specificity in DM/PM patient cohorts were 85% and 92%, 90% and 96%, and 92% and 98% for minimal, moderate, and major improvement, respectively. Definitions were validated in the clinical trial analysis for differentiating the physician rating of improvement (p<0.001). The response criteria for adult DM/PM consisted of the conjoint analysis model based on absolute per cent change in 6 core set measures, with thresholds for minimal, moderate, and major improvement.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a konsensus $7 D032921
650    _2
$a dermatomyozitida $x terapie $7 D003882
650    _2
$a lidé $7 D006801
650    _2
$a hodnocení výsledků zdravotní péče $x normy $7 D017063
650    _2
$a polymyozitida $x terapie $7 D017285
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a senzitivita a specificita $7 D012680
650    12
$a stupeň závažnosti nemoci $7 D012720
655    _2
$a konsensus - konference $7 D016446
655    _2
$a časopisecké články $7 D016428
655    _2
$a směrnice pro lékařskou praxi $7 D017065
655    _2
$a validační studie $7 D023361
700    1_
$a Rider, Lisa G $u NIEHS, NIH, Bethesda, Maryland, USA.
700    1_
$a Ruperto, Nicolino $u Istituto Giannina Gaslini, Pediatria II - Rheumatologia, PRINTO, Genoa, Italy.
700    1_
$a Bayat, Nastaran $u NIEHS, NIH, Bethesda, Maryland, USA.
700    1_
$a Erman, Brian $u Social and Scientific Systems, Inc., Durham, North Carolina, USA.
700    1_
$a Feldman, Brian M $u The Hospital for Sick Children, Toronto, Ontario, Canada.
700    1_
$a Oddis, Chester V $u University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
700    1_
$a Amato, Anthony A $u Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. $7 gn_A_00005298
700    1_
$a Chinoy, Hector $u Central Manchester University Hospitals NHS Foundation Trust, University of Manchester, Manchester, UK.
700    1_
$a Cooper, Robert G $u University of Liverpool, Liverpool, UK.
700    1_
$a Dastmalchi, Maryam $u Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden.
700    1_
$a Fiorentino, David $u Stanford University, Redwood City, California, USA.
700    1_
$a Isenberg, David $d 1949- $7 xx0231548 $u University College London, London, UK.
700    1_
$a Katz, James D $u NIEHS, NIH, Bethesda, Maryland, USA.
700    1_
$a Mammen, Andrew $u Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
700    1_
$a de Visser, Marianne $u Academic Medical Center, Amsterdam, The Netherlands.
700    1_
$a Ytterberg, Steven R $u Mayo Clinic, Rochester, Minnesota, USA.
700    1_
$a Lundberg, Ingrid E $u Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden.
700    1_
$a Chung, Lorinda $u Stanford University, Redwood City, California, USA.
700    1_
$a Danko, Katalin $u University of Debrecen, Debrecen, Hungary.
700    1_
$a García-De la Torre, Ignacio $u Hospital General de Occidente de la Secretaría de Salud and University of Guadalajara, Guadalajara, México.
700    1_
$a Song, Yeong Wook $u Graduate School of Convergence Science and Technology and Seoul National University Hospital, Seoul, Korea.
700    1_
$a Villa, Luca $u Istituto Giannina Gaslini, Pediatria II - Rheumatologia, PRINTO, Genoa, Italy.
700    1_
$a Rinaldi, Mariangela $u Istituto Giannina Gaslini, Pediatria II - Rheumatologia, PRINTO, Genoa, Italy.
700    1_
$a Rockette, Howard $u University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
700    1_
$a Lachenbruch, Peter A $u NIEHS, NIH, Bethesda, Maryland, USA.
700    1_
$a Miller, Frederick W $u NIEHS, NIH, Bethesda, Maryland, USA.
700    1_
$a Vencovsky, Jiri $u Charles University, Prague, Czech Republic.
700    1_
$a ,
773    0_
$w MED00000444 $t Annals of the rheumatic diseases $x 1468-2060 $g Roč. 76, č. 5 (2017), s. 792-801
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28385805 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20190124083727 $b ABA008
999    __
$a ok $b bmc $g 1238832 $s 984064
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 76 $c 5 $d 792-801 $i 1468-2060 $m Annals of the rheumatic diseases $n Ann Rheum Dis $x MED00000444
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Možnosti archivace